Vismodegib (NCT05538091)

Name: Vismodegib trial for Platinum-Resistant Fallopian Tube Carcinoma (NCT05538091)
Uploaded: 2026-10-31T23:52:21.109Z
Duration: 1 min 18 s
Description: Vismodegib trial for Platinum-Resistant Fallopian Tube Carcinoma (NCT05538091). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05538091.

Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer: a one-minute explainerNCT055380911 min

Vismodegib trial for Platinum-Resistant Fallopian Tube Carcinoma (NCT05538091). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adult women with epithelial ovarian, fallopian-tube, or primary peritoneal cancer progressing during platinum chemotherapy or within six months after it. Disease must be measurable or evaluable.

The idea: vismodegib blocks Hedgehog growth signaling; atezolizumab releases a PD-L1 immune brake. Patients take 150 milligrams of vismodegib daily and receive 1,200 milligrams of atezolizumab every three weeks. Researchers assess safety and tumor response. Tumor specimens for research are required from twelve participants.

This phase 2 study plans 48 patients. Ronald Buckanovich leads at UPMC Hillman, Pittsburgh, the sole recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.